Beyond The REMS: Clozapine Adcomm Shows Why In-Program Assessments Are Not Always Enough

 
• By Sue Sutter
  
Eye glasses focused
Schizophrenics are suffering because of the FDA's "myopic" focus on absolute neutrophil counts with clozapine, patient advocates said. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Product Reviews